Allogene疗法 ALLO 深 沪
等待开盘 05-12 09:30:00 美东时间
2.305
+0.030
+1.32%
华盛通- 最 高2.39
- 今 开2.30
- 成交量 271.04万股
- 最 低 2.22
- 昨 收 2.275
- 总市值 33.19万
- 52周最高 4.46
- 市盈率 静 --
- 换手率 1882.24%
- 52周最低 0.985
- 委 比 41.85%
- 总股本 0.00亿
- 历史最高 55.00
- 量 比 0.96
- 振 幅 7.47%
- 历史最低 0.8621
- 每 手 1
- 风险率 0.48%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多JP Morgan Upgrades Allogene Therapeutics to Neutral
JP Morgan analyst Brian Cheng upgrades Allogene Therapeutics (NASDAQ:ALLO) from Underweight to Neutral.
04-16 23:05
Allogene Therapeutics Launches $175M Public Stock Offering To Fund Clinical Development And Operations
Allogene Therapeutics, Inc. (NASDAQ:ALLO) today announced that it intends to offer and sell, in an underwritten public offering and subject to market and other conditions, $175 million of shares of its common stock. All
04-14 04:02
Crude Oil Gains 5%; Fastenal Shares Fall After Q1 Earnings
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gain...
04-14 00:36
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Virax Biolabs Group (NASDAQ:VRAX) stock increased by 76.7% to $0.18 du...
04-13 20:05
Earnings Scheduled For March 12, 2026
Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is likel...
03-12 19:11
Allogene Arbitration Victory Pressures Cellectis Shares Tuesday
Cellectis shares fell after Allogene cited a favorable arbitration ruling confirming control of cema-cel and outlining key CAR-T milestones.
2025-12-17 02:09
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
2025-11-06 19:12
Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO
Allogene Therapeutics reported that ALLO-316, an allogeneic CAR T therapy targeting CD70, showed a 31% response rate in CD70-positive advanced RCC patients, with four out of five responders maintaining their response and one achieving remission over 12 months. The Phase 1 trial demonstrated efficient CAR T cell expansion and tumor infiltration, alongside manageable safety profiles, underscoring its potential in solid tumor treatment.
2025-06-01 14:45
Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
Autolus Therapeutics' obe-cel CAR T-cell therapy received a positive CHMP opinion, based on the FELIX trial showing high response rates and low toxicity for adult r/r B-ALL patients. The EC is expected to decide on conditional marketing authorization within two months, following FDA and MHRA approvals.
2025-05-23 12:30
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
<p>Allogene Therapeutics将参与五月底至六月底的四场投资者会议，详情请访问其官网www.allogene.com获取直播链接。</p>
2025-05-23 12:30
